Alto Neuroscience, Inc.
ANRO · XNYSCIK 1999480fmd_0JZG1PPZZ4V87AHKWQA6P1SSRNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 30 | 47 | 46 |
| Total operating expenses | 38 | 69 | 66 |
| Operating income | (38) | (69) | (66) |
| Interest expense | 1 | 1 | 2 |
| Interest and investment income | 2 | 9 | 7 |
| Other non-operating income (expense) | 2 | 7 | 3 |
| Income tax expense | 0 | 0 | 0 |
| Net income | (36) | (61) | (63) |